Multiple Endocrine Neoplasia Type 1 (MEN1)

USMLE Step 1 trap: Incorrectly includes medullary thyroid carcinoma in MEN1 instead of correctly placing it in MEN2. MEN1 consists of parathyroid hyperplasia/adenoma, pituitary adenoma (most often prolactinoma), and pancreatic islet cell tumors (most often gastrinoma); thyroid is not involved.

MEN1 (Wermer syndrome) is defined by the '3 P's' — Parathyroid, Pituitary, and Pancreas — and USMLE Step 1 tests it from multiple angles. Students consistently make two errors: attributing MEN1 to a RET mutation (that's MEN2) and listing medullary thyroid carcinoma as a component (that also belongs to MEN2). MEN1 is caused by loss-of-function mutation in the MEN1 tumor suppressor gene encoding menin on chromosome 11, and follows autosomal dominant inheritance. The exam tests feature recognition, genetics, and screening protocols for at-risk family members.

The exam hits MEN1 from two main angles: feature recognition (can you name the triad and its most common tumors?) and management (what screening do family members need?). For features, you need to know that parathyroid hyperplasia causing hypercalcemia is the most common and earliest manifestation — not the pituitary tumor. Pancreatic tumors are often gastrinomas causing Zollinger-Ellison syndrome, but insulinomas also show up. For pituitary, prolactinoma dominates. Screening questions ask about biochemical surveillance (calcium, PTH, prolactin, gastrin, fasting glucose) and imaging for at-risk family members with confirmed MEN1 mutations.

What makes MEN1 tricky is the overlap with MEN2 in students' minds. The biggest traps are: (1) attributing MEN1 to a RET mutation — that's MEN2, not MEN1; (2) including medullary thyroid carcinoma in the MEN1 triad — that belongs in MEN2A; and (3) calling the pituitary adenoma the most common presentation when hyperparathyroidism actually leads the pack. USMLE Step 1 loves to exploit exactly these confusions, so getting the genetics and organ list airtight is essential.

From real student decks

59%have cards covering this topic

38%have mature cards

1.0median lapses in 14 days

Common misconceptions

Common mistake

Wrong: MEN1 includes medullary thyroid carcinoma as one of its components.

Right: MEN1 consists of parathyroid hyperplasia/adenoma, pituitary adenoma (most often prolactinoma), and pancreatic islet cell tumors (most often gastrinoma); thyroid is not involved.

Medullary thyroid carcinoma (MTC) is the hallmark of MEN2A and MEN2B — it has no place in MEN1. MEN1 is strictly parathyroid + pituitary + pancreatic islets. The thyroid confusion likely comes from lumping all MEN syndromes together; the clearest fix is to remember that if you see MTC, you're in MEN2 territory, full stop.

Common mistake

Wrong: Pituitary adenoma is the most common initial manifestation of MEN1.

Right: Hyperparathyroidism from parathyroid hyperplasia or adenoma is the most common and often earliest manifestation of MEN1.

Hyperparathyroidism is both the most common and usually the earliest clinical finding in MEN1 — it shows up in over 90% of patients and often precedes other manifestations by years. The pituitary adenoma (usually prolactinoma) is present in roughly 30-40% of cases and rarely leads the presentation. On a vignette showing a young patient with recurrent kidney stones and hypercalcemia alongside other endocrine findings, MEN1 with hyperparathyroidism should be top of your list.

Common mistake

Wrong: MEN1 is caused by a RET proto-oncogene mutation.

Right: MEN1 is caused by loss-of-function mutation in the MEN1 tumor suppressor gene (menin) on chromosome 11; RET mutations cause MEN2.

MEN1 is caused by loss-of-function mutations in the MEN1 tumor suppressor gene encoding the protein menin, located on chromosome 11q13 — it follows classic two-hit tumor suppressor logic. RET is a proto-oncogene (gain-of-function mutations) responsible for MEN2A and MEN2B as well as familial medullary thyroid carcinoma. These are opposite mechanisms: losing a suppressor (MEN1) vs. activating an oncogene (MEN2/RET). Keeping that distinction sharp prevents a very common USMLE Step 1 trap.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Identify all three components of the MEN1 triad (parathyroid, pituitary, pancreas), name the most common tumor at each site (parathyroid hyperplasia/adenoma, prolactinoma, gastrinoma), and state the causative gene (MEN1/menin, chromosome 11, tumor suppressor, autosomal dominant).
Determine which biochemical markers and imaging studies are used to screen at-risk MEN1 family members who carry the mutation, and understand why early detection matters for each organ system.

Can you avoid these mistakes?

A 32-year-old woman presents with recurrent nephrolithiasis, elevated serum calcium, and elevated PTH. Workup also reveals a pituitary mass secreting prolactin and an elevated fasting gastrin level. What syndrome does she have, what gene is mutated, and on which chromosome does it reside?

A student lists the components of MEN1 as: parathyroid hyperplasia, medullary thyroid carcinoma, and prolactinoma. What is wrong with this list, and which syndrome actually includes medullary thyroid carcinoma?

A patient is newly diagnosed with MEN1. Their first-degree relatives want to know if they are at risk. Which specific biochemical tests would you order annually to screen for the three main organ systems involved in MEN1?

A vignette describes a patient with MEN1. The question asks which manifestation is most likely to have appeared first clinically. What is your answer and why — not just the organ, but the specific pathology and its typical biochemical signature?

Multiple Endocrine Neoplasia Type 1 (MEN1)

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics